AMPEL BioSolutions has announced the development of a new blood test aimed at assessing the risk of cardiovascular disease. The CardioGENE test, which is currently in the works, is designed to predict cardiovascular disease and assist in making informed decisions regarding preventive therapies.
Dr. Armie Grammer, co-founder and chief scientific officer of AMPEL, emphasized the potential of CardioGENE as a vital tool for collecting baseline data on cardiovascular risk. He believes it will also help in monitoring disease progression in high-risk patients.
Understanding Cardiovascular Disease
To appreciate the significance of the CardioGENE test, it is essential to recognize the widespread impact of cardiovascular disease (CVD) both globally and domestically. The World Health Organization (WHO) defines CVD as a range of disorders affecting the heart and blood vessels. This includes conditions such as coronary heart disease, stroke, and deep vein thrombosis.
If left untreated, cardiovascular diseases can lead to severe complications including heart attacks, heart failure, and strokes.
They are the leading cause of death worldwide, accounting for 32% of all deaths in 2019. In the United States, CVD remains the top cause of death, responsible for about 20% of fatalities. In 2022 alone, approximately 702,880 people died from heart disease in the U.S., with one person succumbing to CVD every 33 seconds.
The economic burden of cardiovascular diseases is also significant, costing an estimated $253.2 billion from 2019 to 2020.
Despite these challenges, there are effective ways to manage and prevent cardiovascular diseases through lifestyle changes, medications, surgical interventions, and rehabilitation programs.
However, timely diagnosis is crucial to prevent progression to more severe stages.
The Role of CardioGENE
Dr. Grammer explained that AMPEL’s CardioGENE blood test could serve as a minimally invasive method for predicting cardiovascular disease risk. The test aims to detect inflammatory biomarkers associated with cardiovascular issues and identify potential treatment options for patients.
As AMPEL continues to refine this innovative test, its potential impact on early diagnosis and preventive care could be transformative in managing cardiovascular health.
Related topics:
- San Francisco And Australian Researchers Target Childhood Heart Disease with Stem Cells And AI
- SynCardia Secures Patent for Total Artificial Heart Technology
- Virginia Tech Researchers Investigate Protein to Enhance Heart Failure Treatments